BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 05, 2011
 |  BC Week In Review  |  Company News  |  Deals

Idera, Merck KGaA deal

Idera regained rights to cancer product IMO-2055 following the termination of a 2007 deal with Merck. In July, Idera said Merck would not conduct further development of IMO-2055 after an increased incidence of neutropenia and electrolyte imbalances were reported in a Phase Ib trial to treat squamous cell carcinoma of...

Read the full 240 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >